On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson’s Disease
暂无分享,去创建一个
[1] L. Defebvre,et al. Trial of Deferiprone in Parkinson's Disease. , 2022, The New England journal of medicine.
[2] C. A. Stamerra,et al. Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies , 2022, Oxidative medicine and cellular longevity.
[3] Fudi Wang,et al. Astrocyte-derived hepcidin controls iron traffic at the blood-brain-barrier via regulating ferroportin 1 of microvascular endothelial cells , 2022, Cell Death & Disease.
[4] R. Gordon,et al. Inflammasome Activation in Parkinson’s Disease , 2022, Journal of Parkinson's disease.
[5] A. Hayes,et al. LKB1: An emerging therapeutic target for cardiovascular diseases. , 2022, Life sciences.
[6] M. Sahu,et al. Age-related Mitochondrial Dysfunction in Parkinson's Disease: New Insights Into the Disease Pathology , 2022, Neuroscience.
[7] J. Wischhusen,et al. Neuroinflammation in Parkinson’s Disease – Putative Pathomechanisms and Targets for Disease-Modification , 2022, Frontiers in Immunology.
[8] Marco A. S. Baptista,et al. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update , 2022, Journal of Parkinson's disease.
[9] Margarida M Barroso,et al. DMT1 bridges endosomes and mitochondria to modulate mitochondrial iron translocation , 2022, bioRxiv.
[10] M. Tansey,et al. Inflammation and immune dysfunction in Parkinson disease , 2022, Nature Reviews Immunology.
[11] S. Ho,et al. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease , 2022, Translational neurodegeneration.
[12] J. Duce,et al. Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease , 2022, Dalton transactions.
[13] M. Mandic,et al. Antioxidant and neuroprotective activities of selected 2-pyridones: in vitro and in silico study , 2022, Journal of Molecular Structure.
[14] Qing Wang,et al. The neuroprotective effects and transdifferentiation of astrocytes into dopaminergic neurons of Ginkgolide K on Parkinson’ disease mice , 2022, Journal of Neuroimmunology.
[15] J. Morgan,et al. Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial , 2021, Biomedicines.
[16] N. Davoust,et al. Chronic Exposure to Paraquat Induces Alpha-Synuclein Pathogenic Modifications in Drosophila , 2021, International journal of molecular sciences.
[17] Xiaohong Wang,et al. Ferruginol prevents degeneration of dopaminergic neurons by enhancing clearance of α-synuclein in neuronal cells. , 2021, Fitoterapia.
[18] Weiguang Zhang,et al. The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson's disease , 2021, Redox biology.
[19] C. Miguel,et al. Antioxidant, anti-inflammatory and neuroprotective actions of resveratrol after experimental nervous system insults. Special focus on the molecular mechanisms involved , 2021, Neurochemistry International.
[20] J. Menéndez,et al. Neuroprotective Action of Multitarget 7-Aminophenanthridin-6(5H)-one Derivatives against Metal-Induced Cell Death and Oxidative Stress in SN56 Cells , 2021, ACS chemical neuroscience.
[21] Jin-Soo Park,et al. Neuroprotective effects of 2-Heptyl-3-hydroxy-4-quinolone in HT22 mouse hippocampal neuronal cells. , 2021, Bioorganic & medicinal chemistry letters.
[22] Neena Singh,et al. Release of Iron-Loaded Ferritin in Sodium Iodate-Induced Model of Age Related Macular Degeneration: An In-Vitro and In-Vivo Study , 2021, Antioxidants.
[23] T. Fieblinger,et al. Striatal Control of Movement: A Role for New Neuronal (Sub-) Populations? , 2021, Frontiers in Human Neuroscience.
[24] R. Gan,et al. Effects and Mechanisms of Resveratrol on Aging and Age-Related Diseases , 2021, Oxidative medicine and cellular longevity.
[25] C. Sohn,et al. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes. , 2021, Radiology.
[26] C. Sőti,et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: From antioxidant to epigenetic therapy , 2021, Ageing Research Reviews.
[27] P. Gao,et al. ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1 , 2020, Nature Cancer.
[28] Changyin Yu,et al. Signaling mechanisms underlying inhibition of neuroinflammation by resveratrol in neurodegenerative diseases. , 2020, The Journal of nutritional biochemistry.
[29] L. Dardenne,et al. Cinnamoyl-N-Acylhydrazone-Donepezil Hybrids: Synthesis and Evaluation of Novel Multifunctional Ligands Against Neurodegenerative Diseases , 2020, Neurochemical Research.
[30] C. Klein,et al. Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects , 2020, Journal of Parkinson's disease.
[31] N. Gretskaya,et al. The Neuroprotective Effect of N-Docosahexaenoyldopamine on Degenerating Dopaminergic Neurons of the Mesencephalon , 2020, Biology Bulletin.
[32] Yuqiang Wang,et al. Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways , 2020, Aging.
[33] R. Albin,et al. Current and projected future economic burden of Parkinson’s disease in the U.S. , 2020, npj Parkinson's Disease.
[34] Y. Ke,et al. Brain Hepcidin Suppresses Major Pathologies in Experimental Parkinsonism , 2020, iScience.
[35] Ying Guo,et al. Design, Synthesis and Biological Evaluation of Novel ( E )‐Hydroxystyryl Aralkyl Sulfones as Neuroprotective Agents , 2020 .
[36] O. Soukup,et al. A Perspective on Multi-target Drugs for Alzheimer's Disease. , 2020, Trends in pharmacological sciences.
[37] Ammara Riaz,et al. Biochanin A: A novel bioactive multifunctional compound from nature. , 2020, The Science of the total environment.
[38] N. García,et al. Mechanisms of mitochondrial DNA escape and its relationship with different metabolic diseases. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[39] Benjamin J. Frogley,et al. Metal coordination to bipyridyl carbynes. , 2020, Dalton transactions.
[40] J. Elson,et al. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson’s disease , 2020, Archives of Toxicology.
[41] U. Das,et al. Molecular Basis of the Beneficial Actions of Resveratrol. , 2020, Archives of medical research.
[42] R. Lill,et al. Mechanisms of Mitochondrial Iron-Sulfur Protein Biogenesis. , 2020, Annual review of biochemistry.
[43] D. Koziorowski,et al. Serum levels of hepcidin and interleukin 6 in Parkinson's disease. , 2020, Acta neurobiologiae experimentalis.
[44] V. Shoshan-Barmatz,et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease , 2019, Science.
[45] Aloke K. Dutta,et al. Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia , 2019, Scientific Reports.
[46] Yoichi Chiba,et al. Immunoreactivities for hepcidin, ferroportin, and hephaestin in astrocytes and choroid plexus epithelium of human brains , 2019, Neuropathology : official journal of the Japanese Society of Neuropathology.
[47] L. Di,et al. Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease In Vitro and In Vivo , 2019, Oxidative medicine and cellular longevity.
[48] C. Mawrin,et al. Mitoferrin-1 is required for brain energy metabolism and hippocampus-dependent memory , 2019, Neuroscience Letters.
[49] K. Klotz,et al. The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy. , 2019, Drug discovery today.
[50] Linlin Zhao,et al. Mitochondrial transcription factor A promotes DNA strand cleavage at abasic sites , 2019, Proceedings of the National Academy of Sciences.
[51] Siyi Pan,et al. Isoflavone biochanin A, a novel nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element activator, protects against oxidative damage in HepG2 cells. , 2019, BioFactors.
[52] Yue Wang,et al. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease. , 2019, European journal of medicinal chemistry.
[53] W. V. van IJcken,et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.
[54] W. Mandemakers,et al. Parkinson’s disease protein DJ-1 regulates ATP synthase protein components to increase neuronal process outgrowth , 2019, Cell Death & Disease.
[55] Hao Huang,et al. Insights on the Multifunctional Activities of Magnolol , 2019, BioMed research international.
[56] Hui Zhang,et al. Loss of PINK1 causes age-dependent decrease of dopamine release and mitochondrial dysfunction , 2019, Neurobiology of Aging.
[57] K. Kalia,et al. Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums. , 2019, ACS chemical neuroscience.
[58] M. Reith,et al. Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease. , 2018, ACS chemical neuroscience.
[59] M. G. Savelieff,et al. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. , 2018, Chemical reviews.
[60] K. Mohanakumar,et al. Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics , 2017, Journal of Chemical Neuroanatomy.
[61] Eyal Oren,et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.
[62] M. Roth,et al. Regulators of hepcidin expression. , 2019, Vitamins and hormones.
[63] C. Sue,et al. New insights into the complex role of mitochondria in Parkinson’s disease , 2019, Progress in Neurobiology.
[64] B. Bloem,et al. The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.
[65] A. Hoffbrand,et al. The Role of Deferiprone in Iron Chelation. , 2018, The New England journal of medicine.
[66] M. Youdim. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases , 2018, Journal of Neural Transmission.
[67] H. Cai,et al. Parkin and PINK1 mitigate STING-induced inflammation , 2018, Nature.
[68] A. Hevener,et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation , 2018, Nature.
[69] Y. Surova,et al. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders , 2018, Alzheimer's & Dementia.
[70] Ricardo D. Fernández,et al. Iron Redox Chemistry Promotes Antiparallel Oligomerization of α-Synuclein. , 2018, Journal of the American Chemical Society.
[71] T. Südhof,et al. Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.
[72] Zhenming Hu,et al. Resveratrol ameliorates autophagic flux to promote functional recovery in rats after spinal cord injury , 2018, Oncotarget.
[73] Aikseng Ooi,et al. The Roles of NRF2 in Modulating Cellular Iron Homeostasis , 2017, Antioxidants & redox signaling.
[74] M. Núñez,et al. Development of an iron-selective antioxidant probe with protective effects on neuronal function , 2017, PloS one.
[75] L. Bubacco,et al. Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease , 2017, Neurobiology of Disease.
[76] E. H. Howlett,et al. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease , 2017, Human molecular genetics.
[77] Souvarish Sarkar,et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease , 2017, npj Parkinson's Disease.
[78] J. Bolaños,et al. Mitochondrial respiratory chain disorganization in Parkinson's disease-relevant PINK1 and DJ1 mutants , 2017, Neurochemistry International.
[79] Aloke K. Dutta,et al. D‐512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats , 2017, British journal of pharmacology.
[80] M. Núñez,et al. Cell death induced by mitochondrial complex I inhibition is mediated by Iron Regulatory Protein 1. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[81] J. Andersen,et al. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo , 2017, Neuropharmacology.
[82] Khalid Bashir,et al. Status, supply chain and processing of cocoa - A review , 2017 .
[83] A. F. Schinder,et al. αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson’s disease , 2017, Scientific Reports.
[84] Ya-lei Jin,et al. Chocolate Consumption and Risk of Coronary Heart Disease, Stroke, and Diabetes: A Meta-Analysis of Prospective Studies , 2017, Nutrients.
[85] U. Förstermann,et al. Antioxidant effects of resveratrol in the cardiovascular system , 2017, British journal of pharmacology.
[86] Maneesh C. Patel,et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease , 2017, Scientific Reports.
[87] R. Palmiter,et al. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson’s disease-like non-motor symptoms without loss of dopamine neurons , 2017, Scientific Reports.
[88] P. Plastina,et al. N-Docosahexaenoyl Dopamine, an Endocannabinoid-like Conjugate of Dopamine and the n-3 Fatty Acid Docosahexaenoic Acid, Attenuates Lipopolysaccharide-Induced Activation of Microglia and Macrophages via COX-2. , 2017, ACS chemical neuroscience.
[89] Olivier Michielin,et al. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.
[90] Yuqiang Wang,et al. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson’s Disease Model , 2017, Journal of Molecular Neuroscience.
[91] M. Reith,et al. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease. , 2017, ACS chemical neuroscience.
[92] M. Núñez,et al. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease. , 2017, ACS chemical neuroscience.
[93] Raymond Scott Turner,et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease , 2017, Journal of Neuroinflammation.
[94] H. Fox,et al. Loss of Pink1 modulates synaptic mitochondrial bioenergetics in the rat striatum prior to motor symptoms: concomitant complex I respiratory defects and increased complex II‐mediated respiration , 2016, Proteomics. Clinical applications.
[95] A. Mason,et al. Erythroid cell mitochondria receive endosomal iron by a "kiss-and-run" mechanism. , 2016, Biochimica et biophysica acta.
[96] Yong-Xiang Chen,et al. Phosphorylation induces distinct alpha-synuclein strain formation , 2016, Scientific Reports.
[97] M. Jimenez-Del-Rio,et al. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson’s Disease , 2016, Neurochemical Research.
[98] V. Dixit,et al. Inflammasomes: mechanism of assembly, regulation and signalling , 2016, Nature Reviews Immunology.
[99] Caitlyn W. Barrett,et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease , 2016, Science Translational Medicine.
[100] Vincent Zoete,et al. A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules , 2016, ChemMedChem.
[101] M. Núñez,et al. Parkinson's Disease: The Mitochondria-Iron Link , 2016, Parkinson's disease.
[102] Ahmed Negida,et al. Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. , 2016, CNS & neurological disorders drug targets.
[103] D. Turnbull,et al. Mitochondrial DNA Depletion in Respiratory Chain–Deficient Parkinson Disease Neurons , 2016, Annals of neurology.
[104] Subramanian Rajagopalan,et al. Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease , 2016, The Journal of Neuroscience.
[105] J. N. Gattward,et al. Cocoa and Human Health: From Head to Foot—A Review , 2016, Critical reviews in food science and nutrition.
[106] Chankyu Park,et al. Biochanin A Ameliorates Arsenic-Induced Hepato- and Hematotoxicity in Rats , 2016, Molecules.
[107] M. Reddy,et al. Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and Apoptotic Cell Death in a Cell Culture Model of Parkinson's Disease , 2014, Parkinson's disease.
[108] Yuan Sheng,et al. Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain. , 2016, Free radical biology & medicine.
[109] Chuen-Mao Yang,et al. NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review , 2015, Front. Mol. Neurosci..
[110] O. Isacson,et al. Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition , 2015, Molecular Neurobiology.
[111] R. Palmiter,et al. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo , 2015, Neurobiology of Aging.
[112] M. Jensen,et al. Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons , 2015, Neurobiology of Disease.
[113] H. P. Adamo,et al. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity. , 2015, Biochimica et biophysica acta.
[114] Xingshu Li,et al. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease. , 2015, Bioorganic & medicinal chemistry.
[115] D. Klenerman,et al. Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons , 2015, Cell Death and Disease.
[116] H. Lorenz,et al. Intramembrane protease PARL defines a negative regulator of PINK1- and PARK2/Parkin-dependent mitophagy , 2015, Autophagy.
[117] V. Tiranti,et al. Mitochondria: A crossroads for lipid metabolism defect in neurodegeneration with brain iron accumulation diseases. , 2015, The international journal of biochemistry & cell biology.
[118] X. Duan,et al. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron , 2015, Free radical research.
[119] L. Defebvre,et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease , 2015, BMC Neurology.
[120] V. Zurawski,et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging , 2015, Neurobiology of Aging.
[121] P. Chan,et al. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys , 2015, Neuroscience.
[122] R. Means,et al. Mitochondrial DNA Stress Primes the Antiviral Innate Immune Response , 2014, Nature.
[123] J. Obeso,et al. Clinical and pathological features of Parkinson's disease. , 2015, Current topics in behavioral neurosciences.
[124] X. Qi,et al. Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. , 2015, Biochimica et biophysica acta.
[125] Y. Ke,et al. Hepcidin Suppresses Brain Iron Accumulation by Downregulating Iron Transport Proteins in Iron-Overloaded Rats , 2015, Molecular Neurobiology.
[126] Z. Xia,et al. Maneb-induced dopaminergic neuronal death is not affected by loss of mitochondrial complex I activity: results from primary mesencephalic dopaminergic neurons cultured from individual Ndufs4+/+ and Ndufs4−/− mouse embryos , 2014, Neuroreport.
[127] M. Youdim,et al. Molecular targets of the multifunctional iron‐chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus , 2014, British journal of pharmacology.
[128] K. Brockmann,et al. Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease? , 2014, Antioxidants & redox signaling.
[129] M. Martinoli,et al. Resveratrol as a protective molecule for neuroinflammation: a review of mechanisms. , 2014, Current pharmaceutical biotechnology.
[130] S. Mandel,et al. The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. , 2014, Current Alzheimer Research.
[131] A. Mackay-Sim,et al. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction , 2014, Human molecular genetics.
[132] T. Dawson,et al. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily , 2013, Human molecular genetics.
[133] M. Boska,et al. Early Expression of Parkinson’s Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats , 2014, Molecular Neurobiology.
[134] L. Defebvre,et al. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .
[135] Victoria Tapia,et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells , 2013, Journal of neurochemistry.
[136] Norihiro Suzuki,et al. Parkin-catalyzed Ubiquitin-Ester Transfer Is Triggered by PINK1-dependent Phosphorylation* , 2013, The Journal of Biological Chemistry.
[137] Jun Wang,et al. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons. , 2013, Biochimica et biophysica acta.
[138] J. Mehta,et al. Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis , 2013, Scientific Reports.
[139] M. Kruer. The neuropathology of neurodegeneration with brain iron accumulation. , 2013, International review of neurobiology.
[140] A. Ramírez,et al. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome , 2012, Neurobiology of Aging.
[141] E. Giaime,et al. Loss of DJ-1 Does Not Affect Mitochondrial Respiration but Increases ROS Production and Mitochondrial Permeability Transition Pore Opening , 2012, PloS one.
[142] Christine Klein,et al. Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease , 2012, Science Translational Medicine.
[143] E. Bézard,et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration , 2012, Proceedings of the National Academy of Sciences.
[144] P. Spano,et al. 1B/(−)IRE DMT1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NF-κB/RelA Acetylation at Lys310 , 2012, PloS one.
[145] M. Youdim,et al. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice , 2012, Mechanisms of Ageing and Development.
[146] C. Chu,et al. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy , 2012, Neurobiology of Disease.
[147] F. Sterky,et al. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. , 2012, Human molecular genetics.
[148] M. Núñez,et al. Iron toxicity in neurodegeneration , 2012, BioMetals.
[149] Xiongwei Zhu,et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. , 2012, Human molecular genetics.
[150] P. Spano,et al. 1 B / ( 2 ) IRE DMT 1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NFk B / RelA Acetylation at Lys 310 , 2012 .
[151] R. Palmiter,et al. Mitochondrial complex III stabilizes complex I in the absence of NDUFS4 to provide partial activity. , 2012, Human molecular genetics.
[152] D. Hinkle,et al. DJ-1 knock-down impairs astrocyte mitochondrial function , 2011, Neuroscience.
[153] S. Mandel,et al. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain , 2011, Neuroscience.
[154] E. Hirsch,et al. Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. , 2011, Biochemical and biophysical research communications.
[155] B. Galy,et al. Iron Regulatory Protein 1 Outcompetes Iron Regulatory Protein 2 in Regulating Cellular Iron Homeostasis in Response to Nitric Oxide* , 2011, The Journal of Biological Chemistry.
[156] R. Nussbaum,et al. Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦ , 2011, The Journal of Biological Chemistry.
[157] J. Tschopp,et al. A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.
[158] F. B. Davis,et al. Resveratrol and apoptosis , 2011, Annals of the New York Academy of Sciences.
[159] Roberta J. Ward,et al. Brain iron metabolism and its perturbation in neurological diseases , 2011, Journal of Neural Transmission.
[160] Mark R. Cookson,et al. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.
[161] H. Mortiboys,et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 , 2010, Neurology.
[162] Armin Giese,et al. Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.
[163] Wei Li,et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. , 2010, Antioxidants & redox signaling.
[164] M. Vila,et al. Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins , 2010, Annals of neurology.
[165] N. Bonini,et al. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function , 2010, Proceedings of the National Academy of Sciences.
[166] P. Barter,et al. Evidence That Niacin Inhibits Acute Vascular Inflammation and Improves Endothelial Dysfunction Independent of Changes in Plasma Lipids , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[167] N. Hattori,et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.
[168] M. Reith,et al. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkins , 2010, Journal of medicinal chemistry.
[169] J. Tschopp,et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.
[170] P. Klivényi,et al. Novel therapeutic strategies in Parkinson’s disease , 2010, European Journal of Clinical Pharmacology.
[171] Ted M. Dawson,et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.
[172] Hong Jiang,et al. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells , 2009, Neurobiology of Aging.
[173] A H V Schapira,et al. Levodopa in the treatment of Parkinson’s disease , 2009, European journal of neurology.
[174] R. Lill. Function and biogenesis of iron–sulphur proteins , 2009, Nature.
[175] A. Ariza,et al. Molecular Pathology of Lewy Body Diseases , 2009, International journal of molecular sciences.
[176] Xin Zhao,et al. Mitochondrial localization of DJ‐1 leads to enhanced neuroprotection , 2009, Journal of neuroscience research.
[177] Z. Qian,et al. Role of hepcidin in murine brain iron metabolism , 2009, Cellular and Molecular Life Sciences.
[178] B. Bacon,et al. Expression of iron-related genes in human brain and brain tumors , 2009, BMC Neuroscience.
[179] B. Paw,et al. Regulation of Mitochondrial Iron Import through Differential Turnover of Mitoferrin 1 and Mitoferrin 2 , 2008, Molecular and Cellular Biology.
[180] M. Beal,et al. Mitochondrial Approaches for Neuroprotection , 2008, Annals of the New York Academy of Sciences.
[181] R. Palmiter,et al. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat , 2008, Proceedings of the National Academy of Sciences.
[182] Jie Shen,et al. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress , 2008, Proceedings of the National Academy of Sciences.
[183] D. Eliezer,et al. Structural effects of Parkinson's disease linked DJ‐1 mutations , 2008, Protein science : a publication of the Protein Society.
[184] M. Chesselet,et al. Animal models of Parkinson’s disease progression , 2008, Acta Neuropathologica.
[185] Hui Yang,et al. Environmental toxins and α-synuclein in Parkinson’s disease , 2007, Molecular Neurobiology.
[186] P. Emson,et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.
[187] T. Mitsui,et al. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. , 2006, Biochemical and biophysical research communications.
[188] O. von Bohlen und Halbach,et al. Distribution of the iron‐regulating protein hepcidin in the murine central nervous system , 2006, Journal of neuroscience research.
[189] U. Brunk,et al. Intralysosomal iron chelation protects against oxidative stress‐induced cellular damage , 2006, The FEBS journal.
[190] J. Xie,et al. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.
[191] A. Brownlie,et al. Mitoferrin is essential for erythroid iron assimilation , 2006, Nature.
[192] Prasad N. Paradkar,et al. Nitric oxide transcriptionally down‐regulates specific isoforms of divalent metal transporter (DMT1) via NF‐κB , 2006, Journal of neurochemistry.
[193] David S. Park,et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[194] S. Mandel,et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.
[195] M. Kruszewski,et al. Induction of iron regulatory protein 1 RNA-binding activity by nitric oxide is associated with a concomitant increase in the labile iron pool: implications for DNA damage. , 2005, Biochemical and biophysical research communications.
[196] M. Youdim,et al. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases , 2005, Mechanisms of Ageing and Development.
[197] M. Youdim,et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. , 2005, Bioorganic & medicinal chemistry.
[198] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[199] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[200] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[201] Francesca Zazzeroni,et al. Ferritin Heavy Chain Upregulation by NF-κB Inhibits TNFα-Induced Apoptosis by Suppressing Reactive Oxygen Species , 2004, Cell.
[202] Mark A. Wilson,et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[203] D. Koziorowski,et al. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. , 2004, Biochimica et biophysica acta.
[204] Francesca Zazzeroni,et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. , 2004, Cell.
[205] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[206] G. Minotti,et al. Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase. , 2002, Biochemistry.
[207] F. Torti,et al. Regulation of ferritin genes and protein. , 2002, Blood.
[208] J. Drapier,et al. Nitric oxide and peroxynitrite promote complete disruption of the [4Fe-4S] cluster of recombinant human iron regulatory protein 1 , 2002, JBIC Journal of Biological Inorganic Chemistry.
[209] V. Uversky,et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.
[210] K. Pantopoulos,et al. Modulation of Cellular Iron Metabolism by Hydrogen Peroxide , 2001, The Journal of Biological Chemistry.
[211] N. Yanagisawa. [A prospect of treatment for Parkinson's disease in the 21st century]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.
[212] K. Davies,et al. Mitochondrial free radical generation, oxidative stress, and aging. , 2000, Free radical biology & medicine.
[213] H. Ichinose,et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.
[214] D. Radisky,et al. Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. , 1998, The Biochemical journal.
[215] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[216] J. Beattie,et al. Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives. , 1993, Journal of medicinal chemistry.
[217] P. Harrison,et al. Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. , 1992, The Biochemical journal.
[218] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[219] J. Lipsick,et al. Determinants of sequence-specific DNA-binding by p48v-myb. , 1991, Oncogene.
[220] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[221] J. A. Watkins,et al. Mobilization of iron from endocytic vesicles. The effects of acidification and reduction. , 1990, The Journal of biological chemistry.
[222] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[223] E. Huehns,et al. In vivo evaluation of hydroxypyridone iron chelators in a mouse model. , 1987, Acta haematologica.
[224] S. Markey,et al. The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[225] P. Ballard,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983, The New England journal of medicine.